CL2022002402A1 - Inhibidores del eif4e y sus usos - Google Patents

Inhibidores del eif4e y sus usos

Info

Publication number
CL2022002402A1
CL2022002402A1 CL2022002402A CL2022002402A CL2022002402A1 CL 2022002402 A1 CL2022002402 A1 CL 2022002402A1 CL 2022002402 A CL2022002402 A CL 2022002402A CL 2022002402 A CL2022002402 A CL 2022002402A CL 2022002402 A1 CL2022002402 A1 CL 2022002402A1
Authority
CL
Chile
Prior art keywords
eif4e
eif4e inhibitors
inhibitors
inhibit
compositions
Prior art date
Application number
CL2022002402A
Other languages
English (en)
Inventor
L Vandeusen Christopher
E Walts Alan
Sun Or Yat
Original Assignee
Pic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pic Therapeutics Inc filed Critical Pic Therapeutics Inc
Publication of CL2022002402A1 publication Critical patent/CL2022002402A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona compuestos que inhiben la actividad de eIF4E, y composiciones y métodos de uso de ellos.
CL2022002402A 2020-03-03 2022-09-02 Inhibidores del eif4e y sus usos CL2022002402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062984543P 2020-03-03 2020-03-03

Publications (1)

Publication Number Publication Date
CL2022002402A1 true CL2022002402A1 (es) 2023-04-21

Family

ID=75173469

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002402A CL2022002402A1 (es) 2020-03-03 2022-09-02 Inhibidores del eif4e y sus usos

Country Status (15)

Country Link
US (2) US11753403B2 (es)
EP (1) EP4114529A1 (es)
JP (1) JP2023515888A (es)
KR (1) KR20220164706A (es)
CN (1) CN115515685B (es)
AR (1) AR121506A1 (es)
AU (1) AU2021230289A1 (es)
BR (1) BR112022017727A2 (es)
CA (1) CA3170411A1 (es)
CL (1) CL2022002402A1 (es)
CO (1) CO2022012594A2 (es)
IL (1) IL296139A (es)
MX (1) MX2022010944A (es)
TW (1) TW202146393A (es)
WO (1) WO2021178488A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2022143985A1 (zh) * 2020-12-31 2022-07-07 清华大学 吡啶-2-胺衍生物及其药物组合物和用途
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) * 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
GB2615307A (en) * 2022-01-28 2023-08-09 Adorx Therapeutics Ltd Antagonist compounds
US20240208961A1 (en) * 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
TW202502760A (zh) * 2023-07-07 2025-01-16 大陸商上海宇道生物技術有限公司 一類羧酸類化合物及其製備方法和應用
WO2025067360A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 一种DGKzeta拮抗剂及其在医药上的应用

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE3905119A1 (de) 1989-02-20 1990-08-23 Bayer Ag Substituierte acrylsaeureester
GB9105771D0 (en) 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
DE4124942A1 (de) 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US5654322A (en) 1992-08-11 1997-08-05 Wakunaga Seiyaku Kabushiki Kaisha Biphenylmethane derivatives and pharmaceuticals containing the same
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JPH07149745A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
US5457004A (en) 1994-05-27 1995-10-10 Eastman Kodak Company Photographic element containing a high dye-yield coupler with methine dye chromophore
AU689972B2 (en) 1994-11-29 1998-04-09 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
EP0858457A1 (de) 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
DE19618528A1 (de) 1996-05-08 1997-11-13 Basf Ag Methin- und Azamethinfarbstoffe auf Basis von Trifluormethylpyridonen
EP1152759A2 (en) 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
TWI283577B (en) 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US6673820B2 (en) 1999-12-02 2004-01-06 Novartis Animal Health Us, Inc. Aminoheterocyclylamides as pesticides and antiparasitic agents
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
WO2001046165A2 (en) 1999-12-16 2001-06-28 Novartis Ag N-heteroaryl-amides and their use as parasiticides
JP2001269010A (ja) 2000-03-27 2001-10-02 Iseki & Co Ltd ロ−タリの尾輪等取付装置
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6667326B1 (en) 2000-11-16 2003-12-23 Novartis Animal Health Us, Inc. Pesticidal aminoheterocyclamide compounds
EP1351686A2 (en) 2000-11-20 2003-10-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
WO2003002062A2 (en) * 2001-06-29 2003-01-09 Tularik Inc. Bis-aryl thiazole derivatives
US20030158199A1 (en) 2002-01-25 2003-08-21 Kylix, B.V. Novel compounds for inhibition of Tie-2
EP1467981A1 (en) 2002-01-25 2004-10-20 Kylix Pharmaceuticals B.V. 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0214139D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
CA2493712A1 (en) 2002-08-07 2004-02-19 F. Hoffmann-La Roche Ag Aminothiazole derivatives as npy5 receptor inhibitors
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
JP4847868B2 (ja) 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
AR046698A1 (es) 2003-11-11 2005-12-21 Ishihara Sangyo Kaisha Derivado bifenilo o su sal, y pesticida que lo contienen como un ingrediente activo
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
KR20070030196A (ko) 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
US20050227989A1 (en) 2004-04-13 2005-10-13 Icagen, Inc. Polycyclic thiazoles as potassium ion channel modulators
NZ550114A (en) 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
KR20060017929A (ko) 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
DK1789390T3 (da) 2004-09-02 2012-02-27 Genentech Inc Pyridyl-inhibitorer af hedgehog-signalering
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CA2619153C (en) 2005-01-21 2013-12-31 President And Fellows Of Harvard College Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
CN101128445B (zh) 2005-02-24 2012-01-18 日本农药株式会社 4-环丙基-1,2,3-噻二唑化合物，用于农业和园艺用途的植物病害控制剂和其使用方法
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
NZ563866A (en) 2005-05-09 2011-03-31 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
TWI410406B (zh) 2005-05-13 2013-10-01 Otsuka Pharma Co Ltd 吡咯烷化合物
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
DE102005062991A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
DE102005062990A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Thiazole und ihre Verwendung zur Herstellung von Arzneimitteln
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2637172A1 (en) 2006-01-27 2007-08-09 Array Biopharma Inc. Pyridin-2-amine derivatives and their use as glucokinase activators
US7943646B2 (en) 2006-01-31 2011-05-17 Dong Wha Pharmaceutical Co., Ltd. Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same
JP2007254317A (ja) 2006-03-22 2007-10-04 Nippon Nohyaku Co Ltd 増収剤及びその使用方法
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
WO2007118149A2 (en) 2006-04-07 2007-10-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical Lollege Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
KR101130380B1 (ko) * 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
MX2009004785A (es) * 2006-10-31 2009-06-05 Schering Corp Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
JP5219465B2 (ja) 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008091770A1 (en) 2007-01-24 2008-07-31 Array Biopharma Inc. 2-aminopyridine derivatives as glucokinase activators
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
US8362037B2 (en) 2007-03-23 2013-01-29 Array Biopharma, Inc. 2-aminopyridine analogs as glucokinase activators
WO2008121570A1 (en) 2007-03-29 2008-10-09 Irm Llc Compounds and methods for modulating g protein-coupled receptors
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
WO2009017346A1 (en) 2007-07-27 2009-02-05 Dong Wha Pharmaceutical Co., Ltd. Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5567481B2 (ja) 2007-10-09 2014-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとして有用なピリジン誘導体
CA2703978A1 (en) 2007-10-29 2009-05-07 Schering Corporation Thiazole derivatives as protein kinase inhibitors
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
EP2107054A1 (en) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative compounds and therapeutic uses thereof
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20110176972A1 (en) 2008-05-29 2011-07-21 Saint-Gobain Centre De Recherches et D'Etudes Eur Cellular structure containing aluminium titanate
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20100014090A (ko) 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
WO2010012793A1 (en) 2008-08-01 2010-02-04 Bayer Cropscience Sa Fungicide aminothiazole derivatives
US8008329B2 (en) 2008-08-01 2011-08-30 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
WO2010025870A1 (en) 2008-09-03 2010-03-11 Bayer Cropscience Ag Synergistic combinations of thiadiazol carbonic acid derivatives
CN102245574A (zh) 2008-12-08 2011-11-16 欧洲筛选有限公司 用于治疗代谢疾病的化合物、药物组合物以及方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8318928B2 (en) 2008-12-15 2012-11-27 Glenmark Pharmaceuticals, S.A. Fused imidazole carboxamides as TRPV3 modulators
GB0900388D0 (en) * 2009-01-12 2009-02-11 Addex Pharmaceuticals Sa New compounds
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
EP2507232B1 (en) 2009-12-04 2019-03-20 National Health Research Institutes Proline derivatives
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011076734A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2011076732A1 (en) 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
MX2012014273A (es) * 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
US8969573B2 (en) * 2010-06-28 2015-03-03 President And Fellows Of Harvard College Compounds for the inhibition of cellular proliferation
BR112013002112B1 (pt) 2010-07-29 2021-04-06 Rigel Pharmaceuticals, Inc. Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
AT510456B1 (de) 2010-09-27 2012-11-15 Univ Wien Tech Thiazolamin-derivate als zelldifferenzierungsbeschleuniger
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014505089A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー 無脊椎有害動物を防除するためのイソオキサゾリン誘導体
NO2694640T3 (es) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
CN102775368B (zh) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
US8722670B2 (en) 2011-09-30 2014-05-13 Bristol-Myers Squibb Company Selective NR2B antagonists
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN103159695B (zh) 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
CN102532050A (zh) 2011-12-20 2012-07-04 中国科学院兰州化学物理研究所 一种2-胺基取代的噁(噻)唑衍生物的制备方法
CA2858766A1 (en) 2011-12-23 2013-06-27 Basf Se Isothiazoline compounds for combating invertebrate pests
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
CN103420991B (zh) 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9409901B2 (en) * 2012-10-22 2016-08-09 Bantam Pharmaceutical, Llc Compositions and methods for treating or preventing diseases or disorders associated with misregulated EIF4E
WO2014159938A1 (en) 2013-03-13 2014-10-02 The Broad Institute, Inc. Substituted aminothiazoles for the treatment of tuberculosis
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
KR20160034910A (ko) 2013-07-25 2016-03-30 오엠지 유케이 테크놀로지 리미티드 캡슐화된 촉매
WO2015050984A1 (en) * 2013-10-01 2015-04-09 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
US9745324B2 (en) 2013-12-18 2017-08-29 Merck Sharp & Dohme Corp. Iminothiadiazepane dioxide compounds as BACE inhibitors, compositions, and their use
WO2016022644A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP3303332A1 (en) * 2015-06-01 2018-04-11 Bantam Pharmaceutical, LLC Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
TWI730985B (zh) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
CN109153680B (zh) 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
CN106317050B (zh) 2016-08-24 2018-11-23 烟台大学 一种苯基噻唑衍生物及其制备方法与应用
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
US10479786B2 (en) 2016-12-13 2019-11-19 Princeton Drug Discovery, Inc Protein kinase inhibitors
CN115504986B (zh) 2017-03-03 2024-05-14 江苏豪森药业集团有限公司 凋亡信号调节激酶抑制剂及其制备方法和应用
WO2019134661A1 (zh) 2018-01-03 2019-07-11 南京明德新药研发股份有限公司 异吲哚啉酮及其衍生物作为csf-1r抑制剂
WO2019233456A1 (zh) 2018-06-08 2019-12-12 贝达药业股份有限公司 Erk抑制剂及其应用
JP2021530470A (ja) 2018-06-30 2021-11-11 ナショナル インスティテュート オブ バイオロジカル サイエンシズ, ベイジンNational Institute Of Biological Sciences, Beijing カテプシンｃ阻害剤
US12030875B2 (en) 2018-09-07 2024-07-09 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
CN109456279B (zh) * 2018-10-12 2022-11-22 南华大学 噻唑氨基苯甲酰胺乙酸酯衍生物及其用途
CN109232467B (zh) * 2018-10-12 2022-11-25 南华大学 噻唑氨基苯甲酸衍生物及其用途
CN109320473B (zh) * 2018-10-17 2022-11-22 南华大学 噻唑氨基苯甲酰胺乙酸衍生物及其用途
DK3643713T3 (da) 2018-10-23 2025-11-03 Iomx Therapeutics Ag Heterocykliske kinaseinhibitorer og deres anvendelse
CN110759835B (zh) 2018-12-06 2023-05-30 广州华睿光电材料有限公司 苝醌类有机化合物及其应用
CN111484479B (zh) 2019-01-25 2023-06-13 四川科伦博泰生物医药股份有限公司 氮杂环化合物、包含其的药物组合物及其制备方法和用途
CN111647000B (zh) 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN114502539A (zh) 2019-03-28 2022-05-13 埃萨制药股份有限公司 包含雄激素受体的抑制剂的药物组合物和组合及其用途
CN112778283B (zh) 2019-11-08 2023-02-03 北京夏禾科技有限公司 有机电致发光材料及其器件
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2021211974A1 (en) 2020-04-18 2021-10-21 Inipharm, Inc. Hsd17b13 inhibitors and uses thereof
EP3901151B1 (en) 2020-04-21 2026-04-01 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
CN115720579A (zh) 2020-05-01 2023-02-28 赛丹思科大学 抗细菌和抗真菌的截短侧耳素缀合物
AU2021283892A1 (en) 2020-06-03 2023-02-02 Dana-Farber Cancer Institute, Inc. Inhibitors of transcriptional enhanced associate domain (TEAD) and uses thereof
EP4182310A1 (en) 2020-07-15 2023-05-24 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
PY2157405A (es) 2020-07-15 2022-04-22 Ifm Due Inc Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting
US20240083853A1 (en) 2020-09-30 2024-03-14 Fl2022-001, Inc. Hsd17b13 inhibitors and uses thereof
US20240246977A1 (en) 2020-12-31 2024-07-25 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Also Published As

Publication number Publication date
CN115515685B (zh) 2025-04-08
JP2023515888A (ja) 2023-04-14
IL296139A (en) 2022-11-01
US20220356178A1 (en) 2022-11-10
KR20220164706A (ko) 2022-12-13
CA3170411A1 (en) 2021-09-10
US11753403B2 (en) 2023-09-12
EP4114529A1 (en) 2023-01-11
CO2022012594A2 (es) 2022-09-09
CN115515685A (zh) 2022-12-23
BR112022017727A2 (pt) 2022-11-16
MX2022010944A (es) 2022-11-09
AR121506A1 (es) 2022-06-08
US20230399322A1 (en) 2023-12-14
TW202146393A (zh) 2021-12-16
US12157731B2 (en) 2024-12-03
WO2021178488A1 (en) 2021-09-10
AU2021230289A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CL2022002402A1 (es) Inhibidores del eif4e y sus usos
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
ECSP22029193A (es) Aminas bicíclicas como inhibidoras de la cdk2
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CO2023014770A2 (es) Degradadores de cdk2 y sus usos
CO2022003782A2 (es) Inhibidores de kras g12d
CO2023008362A2 (es) Degradadores de irak y sus usos
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CO2020007244A2 (es) Inhibidores de kras g12c
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2021003373A1 (es) Nuevos inhibidores de egfr
CL2018001360A1 (es) Inhibidores triazol de acc y usos de los mismos
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
CR20190566A (es) Inhibidores de quinasay usos de los mismos
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
BR112021011124A2 (pt) Anelossomos e métodos de uso
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CR20160047A (es) Inhibidores de rorc2 y sus métodos de uso
CL2020001687A1 (es) Nuevos compuestos inhibidores del blanco mecanístico de rapamicina (mtor).
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.